Sotrovimab News and Research

RSS

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

30 Sep 2022

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products

Researchers comparatively evaluated antibody responses against SARS-CoV-2 among immunodeficient individuals pre- and post-intravenous immunoglobulin product infusions.

27 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

16 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

The current study focused on the ability of this nmAb to neutralize Delta, Omicron, and other VOCs, as well as its efficacy when given by the intranasal route in an animal model.

1 Sep 2022

SARS-CoV-2 nucleocapsid antigen levels and patient outcomes

In a new study, researchers assessed the correlation between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) antigen levels and hospitalized patient outcomes.

31 Aug 2022

Case report describes clinical manifestation of monkeypox, SARS-CoV-2, and HIV coinfection

Scientists have recently presented the first documented case of coinfection with monkeypox virus, SARS-CoV-2, and HIV.

23 Aug 2022

Study reveals safety and uptake of sotrovimab against severe SARS-CoV-2 infection in England

In a newly released study, researchers explored the sotrovimab uptake for severe COVID-19 prophylaxis and its safety across the community populations in England.

22 Aug 2022

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Researchers evaluated the neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 sub-variants by therapeutic monoclonal antibodies.

16 Aug 2022

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

In a new study, researchers developed bispecific-antibodies (bsAbs) against SARS-CoV-2 Omicron sub-lineages.

12 Aug 2022

What are the hidden sources of SARS-CoV-2 evolution?

A recent article published in Transplant Infectious Disease examined case reports on SARS-CoV-2 evolution in immunosuppressed cohorts.

2 Aug 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

Efficacy of monoclonal antibodies against Omicron BA.1, BA.2, and BA.5

Researchers evaluate the neutralizing potency of therapeutic monoclonal antibodies against three sub-lineages of the SARS-CoV-2 Omicron variant.

27 Jul 2022

Why Omicron is more infectious than other SARS-CoV-2 variants

Researchers describe SARS-CoV-2 Omicron mutations and their impact on neutralization and infectivity.

25 Jul 2022

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers reported mutations in SARS-CoV-2 Delta and Omicron variants of concern infection cases treated with neutralizing monoclonal antibodies.

20 Jul 2022

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

Researchers developed a novel, rapid and accurate qRT-PCR-based method to detect Omicron sublineages BA.1/BA.1.1 and BA.2 in patient samples.

18 Jul 2022

SARS-CoV-2 Omicron BA.5 tropism shifting back to ancestral strains

In a recent study posted to the medRxiv* pre-print server, researchers from Australia and Switzerland gathered data to help track and manage ongoing and future infection waves by new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron globally.

12 Jul 2022

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

A new study successfully identified a potent neutralization epitope in SARS-related coronaviruses.

6 Jul 2022

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

A recent study posted to the bioRxiv* preprint server supports using mosaic sarbecovirus receptor-binding domain (RBD)-nanoparticles to discover therapeutic pan-variant and pan-sarbecovirus monoclonal antibodies (mAbs) and to induce mAbs by vaccination.

30 Jun 2022